Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 4, 2016

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Primary Immunodeficiency Disease
Interventions
BIOLOGICAL

IgG Next Generation (BT595)

Trial Locations (19)

1097

Investigational site # 3602, Budapest

4400

Investigational site #3603, Nyíregyháza

28007

Investigational site # 3405, Madrid

35294

Investigational site # 0104, Birmingham

43617

Investigational site # 0105, Toledo

46617

Investigational site # 0106, South Bend

60528

Investigational site # 4902, Frankfurt am Main

60612

Investigational site # 0111, Chicago

75231

Investigational Site # 0102, Dallas

79106

Investigational site # 4904, Freiburg im Breisgau

80112

Investigational site # 0103, Centennial

80233

Investigational site # 0114, Thornton

90027

Investigational site # 0116, Los Angeles

117198

Investigational site # 0702, Moscow

620102

Investigational site # 0704, Yekaterinburg

38103-2800

Investigational site #0115, Memphis

04129

Investigational site #4905, Leipzig

Unknown

Investigational Site # 3605, Miskolc

08035

Investigational site # 3403, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Biotest

INDUSTRY